80 related articles for article (PubMed ID: 23869866)
21. Cyclocreatine phosphate, an analogue of creatine phosphate, does not improve hypoxic tolerance in mice.
Artru AA; Michenfelder JD
J Neurochem; 1982 Oct; 39(4):1198-200. PubMed ID: 7119791
[TBL] [Abstract][Full Text] [Related]
22. Role of creatine and phosphocreatine in neuronal protection from anoxic and ischemic damage.
Balestrino M; Lensman M; Parodi M; Perasso L; Rebaudo R; Melani R; Polenov S; Cupello A
Amino Acids; 2002; 23(1-3):221-9. PubMed ID: 12373542
[TBL] [Abstract][Full Text] [Related]
23. Cyclocreatine inhibits the production of neutrophil chemotactic factors from isolated hearts.
Elgebaly SA; Allam ME; Rossomando EF; Cordis GA; Forouhar F; Farghaly A; Kreutzer DL
Am J Pathol; 1990 Nov; 137(5):1233-41. PubMed ID: 2240167
[TBL] [Abstract][Full Text] [Related]
24. Antiproliferative effects of cyclocreatine on human prostatic carcinoma cells.
Hoosein NM; Martin KJ; Abdul M; Logothetis CJ; Kaddurah-Daouk R
Anticancer Res; 1995; 15(4):1339-42. PubMed ID: 7654018
[TBL] [Abstract][Full Text] [Related]
25. Effects of accumulation of phosphocreatine on the survival time of thin hippocampal slices from the guinea pig during deprivation of both oxygen and glucose.
Okada Y; Yoneda K
Neurosci Lett; 1983 Oct; 41(1-2):119-24. PubMed ID: 6646511
[TBL] [Abstract][Full Text] [Related]
26. Acute replacement of phosphocreatine in the isolated rat heart by perfusion with the creatine analogue beta-guanidinopropionic acid.
Unitt JF; Radda GK; Seymour AM
Biochem Soc Trans; 1990 Aug; 18(4):606-7. PubMed ID: 2276461
[No Abstract] [Full Text] [Related]
27. Cyclocreatine (1-carboxymethyl-2-iminoimidazolidine) inhibits growth of a broad spectrum of cancer cells derived from solid tumors.
Lillie JW; O'Keefe M; Valinski H; Hamlin HA; Varban ML; Kaddurah-Daouk R
Cancer Res; 1993 Jul; 53(13):3172-8. PubMed ID: 8319226
[TBL] [Abstract][Full Text] [Related]
28. Antitumor activity of creatine analogs produced by alterations in pancreatic hormones and glucose metabolism.
Ara G; Gravelin LM; Kaddurah-Daouk R; Teicher BA
In Vivo; 1998; 12(2):223-31. PubMed ID: 9627806
[TBL] [Abstract][Full Text] [Related]
29. Cyclocreatine accumulation leads to cellular swelling in C6 glioma multicellular spheroids: diffusion and one-dimensional chemical shift nuclear magnetic resonance microscopy.
Schiffenbauer YS; Tempel C; Abramovitch R; Meir G; Neeman M
Cancer Res; 1995 Jan; 55(1):153-8. PubMed ID: 7805026
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of chronic toxicity of cyclocreatine in beagle dogs after oral gavage administration for up to 23 weeks.
Wallery JJ; Kale VP; Novak J; Gibbs S; Do MT; McKew JC; Terse PS
Toxicol Appl Pharmacol; 2021 Nov; 430():115680. PubMed ID: 34411581
[TBL] [Abstract][Full Text] [Related]
31. Effects of creatine and cyclocreatine supplementation on kainate induced injury in pre-pubescent rats.
Mikati MA; Kurdit RM; Rahmeh AA; Farhat F; Abu Rialy S; Lteif L; Francis E; Geha G; Maraashli W
Brain Inj; 2004 Dec; 18(12):1229-41. PubMed ID: 15666567
[TBL] [Abstract][Full Text] [Related]
32. Kinetics of cyclocreatine and Na(+) cotransport in human breast cancer cells: mechanism of activity.
Maril N; Degani H; Rushkin E; Sherry AD; Cohn M
Am J Physiol; 1999 Oct; 277(4):C708-16. PubMed ID: 10516101
[TBL] [Abstract][Full Text] [Related]
33. Exogenous creatine delays anoxic depolarization and protects from hypoxic damage: dose-effect relationship.
Balestrino M; Rebaudo R; Lunardi G
Brain Res; 1999 Jan; 816(1):124-30. PubMed ID: 9878706
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of creatine analogues as a new class of anticancer agents using freshly explanted human tumor cells.
Martin KJ; Chen SF; Clark GM; Degen D; Wajima M; Von Hoff DD; Kaddurah-Daouk R
J Natl Cancer Inst; 1994 Apr; 86(8):608-13. PubMed ID: 8145276
[TBL] [Abstract][Full Text] [Related]
35. The synthetic phosphagen cyclocreatine phosphate inhibits the growth of a broad spectrum of solid tumors.
Schimmel L; Khandekar VS; Martin KJ; Riera T; Honan C; Shaw DG; Kaddurah-Daouk R
Anticancer Res; 1996; 16(1):375-80. PubMed ID: 8615639
[TBL] [Abstract][Full Text] [Related]
36. Creatine salts provide neuroprotection even after partial impairment of the creatine transporter.
Adriano E; Garbati P; Salis A; Damonte G; Millo E; Balestrino M
Neuroscience; 2017 Jan; 340():299-307. PubMed ID: 26930002
[TBL] [Abstract][Full Text] [Related]
37. Protective effects of some creatine derivatives in brain tissue anoxia.
Perasso L; Lunardi GL; Risso F; Pohvozcheva AV; Leko MV; Gandolfo C; Florio T; Cupello A; Burov SV; Balestrino M
Neurochem Res; 2008 May; 33(5):765-75. PubMed ID: 17940889
[TBL] [Abstract][Full Text] [Related]
38. Developmental changes in hyperexcitability of CA1 pyramidal neurons induced by repeated brief episodes of hypoxia in the rat hippocampal slices.
Levin S; Godukhin O
Neurosci Lett; 2005 Mar; 377(1):20-4. PubMed ID: 15722180
[TBL] [Abstract][Full Text] [Related]
39. Expression of human equilibrative nucleoside transporter 1 in mouse neurons regulates adenosine levels in physiological and hypoxic-ischemic conditions.
Zhang D; Xiong W; Albensi BC; Parkinson FE
J Neurochem; 2011 Jul; 118(1):4-11. PubMed ID: 21395582
[TBL] [Abstract][Full Text] [Related]
40. Liposomal Delivery of Cyclocreatine Impairs Cancer Cell Bioenergetics Mediating Apoptosis.
Ganguly S; Elbayoumi T
Methods Mol Biol; 2021; 2275():173-186. PubMed ID: 34118038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
